Risk for COVID-19 Reinfection Remains Unknown
Jeffrey Shaman, Ph.D., of Climate and Health Program at Columbia University, spoke with HD Live! about COVID-19 reinfection risk
Antibiotic Prescribing High in Low-, Middle-Income Countries
Proportion of patients with inappropriate prescriptions ranged from 8 to 100 percent
Steroid May Reduce COVID-19 Death Risk by Up to One-Third
Dexamethasone appears promising for patients with severe illness
Correlates of COVID-19 ID’d on American Indian Reservations
Rate of cases higher on American Indian reservations with larger proportion of homes lacking plumbing
Therapeutic Hookworm Explored for Relapsing Multiple Sclerosis
No effect seen for hookworm versus placebo on number of new/enlarging/enhancing lesions
Four Months of Rifampin Costs Less Than Nine Months Isoniazid
Health system use and costs higher for nine months of isoniazid in adults and children in all settings
Self-Collected Nasal Swabs Acceptable for SARS-CoV-2 Testing
Diagnostic equivalence seen across patient-collected nasal swabs, doctor-collected nasal, oropharyngeal swabs
Face Masks Most Effective Means to Avert COVID-19 Transmission
Airborne transmission is dominant route for spread; masks are determinant for shaping pandemic trend
Hydroxychloroquine-Remdesivir Combo Dangerous for COVID-19 Patients
FDA says chloroquine or hydroxychloroquine could reduce the antiviral effectiveness of remdesivir
CDC: Cumulative Incidence of COVID-19 403.6 Per 100,000 in U.S.
Hospitalization and mortality six times, 12 times higher for patients reporting an underlying condition